Literature DB >> 3227279

Can deferoxamine be considered an ototoxic drug?

W Masala1, F Meloni, D Gallisai, M Careddu, G Secchi, G B Cuccuru, V Loriga, G Salvo.   

Abstract

Some uncertainty about deferoxamine ototoxicity is to be found in the literature. Therefore, 100 patients affected by beta-thalassemia were checked audiologically. Twelve of them showed a sensorineural hearing impairment which in most cases was confined to 4 and 8 kHz. If these results are compared with a sample of "normal" population, no significant difference can be observed, therefore excluding that deferoxamine, at least at present dosages, may be considered as a certain cause of cochlear impairment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3227279

Source DB:  PubMed          Journal:  Scand Audiol Suppl        ISSN: 0107-8593


  3 in total

Review 1.  Experimental, clinical and preventive aspects of ototoxicity.

Authors:  A A Chiodo; P W Alberti
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

2.  Frequency of sensory neural hearing loss in major Beta-thalassemias in southern iran.

Authors:  Abolhassan Faramarzi; Mehran Karimi; Seyed-Taghi Heydari; Mahmoud Shishegar; Masoud Kaviani
Journal:  Iran J Pediatr       Date:  2010-09       Impact factor: 0.364

Review 3.  Hearing Loss in Beta-Thalassemia: Systematic Review.

Authors:  Immacolata Tartaglione; Roberta Carfora; Davide Brotto; Maria Rosaria Barillari; Giuseppe Costa; Silverio Perrotta; Renzo Manara
Journal:  J Clin Med       Date:  2021-12-25       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.